Drugs / Nemiralisib
Nemiralisib
also known as
GSK2269557 · GSK-2269557 FREE BASE · GSK-2269557A · GSK2269557H · GSK2269557T · NEMI · Nemiralisib hemisuccinate · Nemiralisib hydrochloride · +1 more
Small molecule targets PIK3CD via inhibition
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03398421 | Jan → Mar 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03315559 | Nov → Dec 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03189589 | Jun → Jul 2017 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02972905 | Oct → Dec 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02691325 | Mar → Jun 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01762878 | Jan → Oct 2013 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01462617 | Jul 2011 → Mar 2012 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 26 trials · 2 missed | ||||||
| Phase 2 | NCT03345407 | Nov 2017 → Jan 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT02593539 | Jul 2016 → Jun 2020 | activated PI3K-delta syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02522299 | Nov 2015 → Jun 2018 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02567708 | Oct 2015 → Sep 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT02294734 | Mar 2015 → Feb 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02130635 | Jul 2014 → Aug 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-05-16 | GlaxoSmithKline | Results GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference gsk.com ↗
Inhaled PI3Kdelta Inhibitor Nemiralisib Improves Lung Function and Reduces Re-Exacerbations in Exacerbating Chronic Obstructive Pulmonary Disease (COPD) patients (PII116678) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-05-16 | GlaxoSmithKline | GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference gsk.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nemiralisib | “This randomized, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability, and pharmacokinetics of a PI3Kδ inhibitor, nemiralisib...” PMID 30217958 ↗ Sep 2018 |
| Known as | GSK-2269557 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2216859 ↗ |
| Known as | GSK-2269557A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2216859 ↗ |
| Known as | GSK2269557 | “This randomized, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability, and pharmacokinetics of a PI3Kδ inhibitor, nemiralisib...” PMID 30217958 ↗ Sep 201810“Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)” NCT03345407 ↗ |
| Known as | GSK2269557H | “It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.” NCT03315559 ↗ |
| Known as | GSK2269557T | “It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.” NCT03315559 ↗ |
| Known as | NEMI | “repeat doses of inhaled nemiralisib (NEMI)” NCT02593539 ↗ |
| Known as | Nemiralisib hemisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2216859 ↗ |
| Known as | Nemiralisib hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2216859 ↗ |
| Known as | NEMIRALISIB SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2216859 ↗ |
| Action | Inhibit | “phosphoinositides 3-kinases -delta (PI3K-delta) inhibitor” NCT01762878 ↗1“PI3-kinase p110-delta subunit inhibitor” CHEMBL2216859 ↗ |
| Modality | Small molecule | — CHEMBL2216859 ↗ |
| Route | Inhaled | “nebulised GSK2269557” NCT01462617 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL2216859 ↗ |